Opthea Limited
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Frederic Guerard M.S., Pharm.D.
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 650 Chapel Street South Yarra VIC Australia 3141
- IPO Date
- Oct 16, 2020
- CIK
- 0001815620
- Website
- opthea.com
- Similar Companies
- Business
- Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Company News
Opthea Announces Decision to Discontinue Wet AMD Trials
Opthea Announces COAST Phase 3 Trial Topline Results
Opthea Announces Phase 2b Wet AMD Publication
Opthea to Present at Oppenheimer Healthcare Conference
Opthea Wet AMD Data Featured at Macula Society Meeting
Opthea to Host Investor Days in New York and Australia
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Opthea's Wet AMD Program to be Featured at FLORetina 2024
Opthea Appoints Kathy Connell to Board of Directors
Opthea Wet AMD Program to be Presented at Innovate Retina
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
Opthea Announces Executive Leadership Changes and Senior Hires
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
Opthea Reports Full-Year Financial Results and Business Updates
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens